Tadalafil Effects in Left Ventricle Diastolic Dysfunction in Resistant Hypertensive Patients
Phosphodiesterase-5 Inhibitor (Tadalafil) Two Weeks Administration Period Effects in Left Ventricle Diastolic Dysfunction and BNP Levels in Resistant Hypertensive Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
São Paulo
-
Campinas, São Paulo, Brazil, 13083-970
- Laboratory of Cardiovascular Pharmacology - FCM - Unicamp
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- resistant hypertension (according to Resistant Hypertension - American Heart Association Statement - 2008);
- compliance with antihypertensive treatment;
- age >35 years;
- left ventricle diastolic dysfunction types I and II
Exclusion Criteria:
- valvulopathy
- decompensated heart failure
- important cardiac arrhythmias
- nephropathy
- hepatopathy
- autoimmune disease
- tabagism
- decompensated diabetes
- uncontrolled dislipidemia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: sugar pill
Intervention: sugar pill
|
Sugar pills: 20mg orally, once a day for 2 weeks
Other Names:
|
|
Active Comparator: tadalafil
Intervention: tadalafil
|
Tadalafil pills: 20mg orally, once a day for 2 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Left Ventricle Diastolic Dysfunction
Time Frame: Baseline and 2 weeks
|
Outcome measurement assessed by Echocardiogram before and after a 2-week tadalafil administration period.
|
Baseline and 2 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in endothelial function
Time Frame: baseline and 2 weeks
|
Outcome measure assessed by flow-mediated dilation before and after a 2-week tadalafil administration period.
|
baseline and 2 weeks
|
|
Change in blood pressure levels
Time Frame: Baseline and 2 weeks
|
Blood pressure measurements assessed before and after a 2-week tadalafil administration period.
|
Baseline and 2 weeks
|
|
Change in B-type Natriuretic Peptide (BNP-32) levels
Time Frame: Baseline and 2 weeks
|
Plasma brain natriuretic peptide (BNP-32)assessed before and after a 2-week tadalafil administration period
|
Baseline and 2 weeks
|
|
Change in cyclic guanosine monophosphate (cGMP) levels
Time Frame: Baseline and 2 weeks
|
Cyclic guanosine monophosphate (cGMP) levels assessed before and after a 2-week tadalafil administration period
|
Baseline and 2 weeks
|
|
Change in nitrite levels
Time Frame: Baseline and 2 weeks
|
Nitrite levels assessed before and after a 2-week tadalafil administration period.
|
Baseline and 2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Heitor Moreno-Junior, MD, PhD, Faculty of Medical Sciences - Unicamp
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CAAE 0044.0.146.000-09
- [2009/53430-7] (Other Identifier: FAPESP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.